Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Vera Therapeutics, a late-stage biotechnology firm, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco from January 9-12, 2023. The presentation is scheduled for January 10th at 1:30 PM PT. Vera focuses on treatments for immunological diseases, with its leading candidate, atacicept, targeting autoimmune conditions like IgA nephropathy and lupus nephritis. Investors can access the webcast here, with a replay available for 90 days.

BRISBANE, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 41st Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 9 – 12, 2023. The management team will also participate in one-on-one investor meetings.

Presentation Details:

Date:	Tuesday, January 10th
Time:	1:30 PM PT
Webcast:	https://jpmorgan.metameetings.net/events/healthcare23/sessions/43887-vera/webcast?gpu_only=true&kiosk=true

A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.

About Vera Therapeutics
Vera Therapeutics is a late-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunologic diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. For more information, please visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Uncapped Communications
uncappedverateam@uncappedcommunications.com

FAQ

When is Vera Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Vera Therapeutics will present on January 10, 2023, at 1:30 PM PT.

Where is the J.P. Morgan Healthcare Conference taking place?

The conference is being held in San Francisco, CA from January 9-12, 2023.

What is Vera Therapeutics' lead product candidate?

Vera's lead product candidate is atacicept, which targets autoimmune diseases.

How can I watch the Vera Therapeutics presentation?

The presentation can be accessed via webcast at this link.

Is there a replay available for Vera's presentation?

Yes, a replay will be available for 90 days after the presentation.